| Literature DB >> 31615434 |
Ting Tian1,2, Peng Huang1, Jingjing Wu1, Chunhui Wang3, Haozhi Fan1, Yun Zhang1, Rongbin Yu1, Chao Wu4, Xueshan Xia5, Zuqiang Fu1, Jun Li6, Ming Yue7.
Abstract
BACKGROUND: CD40, encoded by TNFRSF5, participates in the survival of B cells, process of antigen presentation and generation of CD8+ T cell memory. It also has an important effect on HCV antiviral immune response. This study aims to investigate whether TNFRSF5 gene polymorphisms are associated with HCV infection outcomes among Chinese population.Entities:
Keywords: CD 40; Genetic polymorphism; Hepatitis C virus; Infection outcomes; Susceptibility
Year: 2019 PMID: 31615434 PMCID: PMC6792238 DOI: 10.1186/s12879-019-4482-5
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographical and clinical characteristics among HCV control, spontaneous clearance and persistent infection populations
| Variables | Group A (%) | Group B (%) | Group C (%) |
|
|---|---|---|---|---|
| Age (years, mean ± SD) | 52.65 ± 13.30 | 51.12 ± 13.82 | 51.89 ± 12.37 | 0.076a |
| Gender | 0.130b | |||
| Male | 603 (39.9) | 194 (39.1) | 273 (35.5) | |
| Female | 910 (60.1) | 302 (60.9) | 495 (65.5) | |
| ALT (U/L) | < 0.001b | |||
| < 40 | 1421 (94.9) | 387 (78.2) | 443 (57.8) | |
| ≥40 | 77 (5.1) | 108 (21.8) | 323 (42.2) | |
| AST (U/L) | ||||
| < 40 | 1422 (95.1) | 394 (80.9) | 454 (60.0) | < 0.001b |
| ≥40 | 74 (4.9) | 93 (19.1) | 303 (40.0) | |
| Route of infection | < 0.001b | |||
| HD | 553 (36.5) | 91 (18.3) | 76 (9.9) | |
| IVDU | 181 (12.0) | 138 (27.8) | 140 (18.2) | |
| PBD | 779 (51.5) | 267 (53.9) | 552 (71.9) | |
| HCV genotypes | < 0.001b | |||
| 1b | – | 42 (26.3) | 223 (46.1) | |
| Non-1b | – | 118 (73.7) | 261 (53.9) |
Abbreviations: ALT alanine transaminase, AST aspartate aminotransferase, HCV hepatitis C virus, HD hemodialysis, IVDU Intravenous drug user, PBD paid blood donors
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients
a P value of one-way ANOVA among three groups
b P value of χ2-test among three/two groups
Genotypes distributions of TNFRSF5 SNPs among control, spontaneous clearance and persistent infection groups
| SNPs (genotype) | Group A | Group B | Group C | Group (B + C)/Group A | Group C/Group B | ||
|---|---|---|---|---|---|---|---|
| n(%) | n(%) | n(%) | OR(95%CI)a |
| OR(95%CI)b |
| |
| rs1535045 | |||||||
| CC | 688 (46.5) | 214 (43.9) | 328 (43.6) | 1.00 | – | 1.00 | – |
| CT | 648 (43.8) | 211 (43.3) | 322 (42.8) | 1.043 (0.884-1.231) | 0.618 | 0.979 (0.763-1.256) | 0.867 |
| TT | 142 (9.7) | 62 (12.8) | 103 (13.6) |
|
| 1.095 (0.760-1.576) | 0.626 |
| Dominant model | 1.109 (0.948-1.297) | 0.197 | 1.005 (0.796-1.271) | 0.964 | |||
| Additive model | 1.135 (1.011-1.275) | 0.032 | 1.027 (0.869-1.215) | 0.752 | |||
| Recessive model |
|
| 1.106 (0.785-1.559) | 0.564 | |||
| rs1883832 | |||||||
| CC | 567 (39.4) | 178 (37.3) | 275 (37.7) | 1.00 | – | 1.00 | – |
| CT | 693 (48.2) | 217 (45.5) | 333 (45.6) | 1.019 (0.858-1.210) | 0.833 | 1.008 (0.778-1.306) | 0.951 |
| TT | 178 (12.4) | 82 (17.2) | 122 (16.7) |
|
| 0.980 (0.695-1.383) | 0.909 |
| Dominant model | 1.090 (0.926-1.282) | 0.300 | 1.001 (0.785-1.275) | 0.997 | |||
| Additive model | 1.127 (1.004-1.263) | 0.042 | 0.993 (0.841-1.173) | 0.937 | |||
| Recessive model |
|
| 0.976 (0.713-1.335) | 0.878 | |||
| rs4810485 | |||||||
| GG | 604 (40.6) | 190 (39.7) | 306 (41.0) | 1.00 | – | 1.00 | – |
| GT | 693 (46.6) | 211 (44.1) | 328 (43.9) | 0.970 (0.819-1.148) | 0.721 | 0.981 (0.761-1.266) | 0.885 |
| TT | 191 (12.8) | 78 (16.2) | 113 (15.1) | 1.201 (0.944-1.527) | 0.136 | 0.927 (0.655-1.312) | 0.667 |
| Dominant model | 1.021 (0.871-1.196) | 0.802 | 0.967 (0.762-1.227) | 0.780 | |||
| Additive model | 1.063 (0.949-1.190) | 0.290 | 0.967 (0.819-1.141) | 0.688 | |||
| Recessive model | 1.220 (0.976-1.526) | 0.081 | 0.936 (0.679-1.290) | 0.685 | |||
Abbreviations: CI confidence interval, HCV hepatitis C virus, OR odds ratio, SNP single nucleotide polymorphism
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): Infected individuals
aThe P value, OR and 95% CIs of Group (B + C) versus Group A were calculated on the basis of the logistic regression model, adjusted by gender, age and routes of infection
bThe P value, OR and 95% CIs of Group C versus Group B were calculated on the basis of the logistic regression model, adjusted by gender, age and routes of infection
Bonferroni correction was applied and the P value was adjusted to 0.0167 (0.05/3)
Bold type indicates statistically significant results
Stratified analysis of rs1535045 and rs1883832 among control, spontaneous clearance and persistent infection groups
| SNPs | Allele | Subgroups | Group (B + C)/Group A | ||
|---|---|---|---|---|---|
| OR(95%CI)a |
|
| |||
| rs1535045 | C/T | Age | |||
| <50 | 1.417 (0.973-2.064) | 0.069 | 0.787 | ||
| ≥50 | 1.323 (0.955-1.832) | 0.092 | |||
| Gender | |||||
| male | 1.240 (0.764-1.652) | 0.551 | 0.158 | ||
| female |
|
| |||
| Routes of infection | |||||
| HD | 1.285 (0.684-2.413) | 0.436 | 0.479 | ||
| Drug user | 0.985 (0.607-1.598) | 0.951 | |||
| PBD |
|
| |||
| rs1883832 | C/T | Age | |||
| <50 |
|
| 0.572 | ||
| ≥50 | 1.297 (0.979-1.719) | 0.070 | |||
| Gender | |||||
| male |
|
| 0.344 | ||
| female | 1.228 (0.917-1.646) | 0.168 | |||
| Routes of infection | |||||
| HD |
|
| 0.066 | ||
| Drug user |
|
| |||
| PBD | 1.111 (0.839 -1.471) | 0.168 | |||
Abbreviations: CI confidence interval, HD hemodialysis, PBD paid blood donors, OR odds ratio
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): HCV-infected individuals
a The P value, OR and 95% CIs of group (B + C) versus Group A were calculated on the basis of the binary logistic regression model, adjusted by gender, age and routes of infection in recessive model (TT versus [TC + CC])
b The P value for the heterogeneity test
Bold type indicates statistically significant results
Cumulative effects of combined risk alleles (rs1535045 T and rs1883832 T) on the susceptibility to HCV infection
| Variables | Group A | Group B+ Group C | Group (B + C)/Group A | |
|---|---|---|---|---|
| n | n | OR(95%CI)a |
| |
| 0 | 154 | 123 | 1 | |
| 1 | 619 | 444 | 0.965 (0.734-1.269) | 0.799 |
| 2 | 615 | 550 | 1.179 (0.899-1.546) | 0.233 |
| 3 4 | 29 | 64 |
|
|
| Trend |
| |||
| 0 | 154 | 123 | 1 | |
| 1-4 | 1362 | 1138 | 1.114 (0.862-1.440) | 0.411 |
Abbreviations: HCV hepatitis C virus, OR odds ratio,95% CI 95% confidence interval
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): HCV-infected individuals
aLogistic regression model, adjusted for gender, age, and routes of infection
bCochran–Armitage trend test
Bold type indicates statistically significant results
Haplotype analysis of rs1535045 and rs1883832 in the study population
| Variables | Group A | Group B+ Group C | Group (B + C)/Group A | |
|---|---|---|---|---|
| n | n | OR(95%CI)a |
| |
| CC | 985 | 728 | 1 | |
| CT | 1087 | 929 |
|
|
| TC | 927 | 789 |
|
|
| TT | 33 | 76 |
|
|
Abbreviations: HCV hepatitis C virus, OR odds ratio, 95% CI 95% confidence interval
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): HCV-infected individuals
aLogistic regression model, adjusted for gender, age and routes of infection
Bold type indicates statistically significant results
Fig. 1The functional annotations of rs1883832, rs4810485 and rs1535045 in UCSC genome browser were listed in this figure. SNPs marked with blue vertical lines (rs1883832, rs4810485, rs1535045 arranged from left to right) are located within the putative promoter transcription regulatory region characterized by Transcription Levels, histone protein modification (H3k4me1, H3k4me3 and H3k27AC) and DNase Hypersensitivity clusters
Fig. 2Expression quantitative trait loci (eQTL) analysis of rs1883832 with CD40 mRNA expression levels in the whole blood samples. The results showed that minor T allele of rs1883832 were pronouncedly associated with decreased expression levels of CD40. The P values were derived from linear regression model. This data was obtained from Genotype-Tissue Expression project (GTEx V6p) Portal